New York, NY, Alpharetta, GA, Tel Aviv, ISRAEL and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) — through NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a complete medical diagnostics and associated options firm, at the moment introduced that it has entered right into a Letter of Intent with Acumen Diagnostics Pte Ltd of Singapore for its CLIA/CAP licensed medical testing laboratory Provista Diagnostics to license the laboratory developed take a look at (LDT) rights to commercialize the sepsis PCR-based diagnostic take a look at AcuSept within the USA. AcuSept is a number (affected person) immune response take a look at that identifies 19 mRNA biomarkers of an infection, sepsis and septic shock and can be utilized to observe the affected person’s response to remedy. Below the phrases of the settlement, Provista may even conduct medical validation research of AcuSept to generate the information within the US to assist Acumen Diagnostics’ 510(okay) submission to the US Meals & Drug Administration.
In keeping with the Sepsis Alliance, sepsis is the #1 main explanation for demise in US hospitals, has an financial value to the US well being care system of at the least $62 billion yearly, and is the main explanation for US hospital readmission. Hospitalized COVID-19 sufferers are 300% extra prone to develop septic shock in comparison with hospitalized flu sufferers. The danger of creating septic shock will increase by 4-9% per undiagnostic hour with sepsis.
AcuSept can present a sepsis end result inside 5 hours of affected person sampling; medical research carried out by Acumen Diagnostics had proven that AcuSept detected sepsis with superior sensitivity in comparison with different single-biomarker checks and proved to be extremely efficient in diagnosing culture-negative sepsis. AcuSept detected an infection in sufferers with superior constructive and unfavorable predictive values, offering complementary information to pathogen identification checks, together with PCR-based checks at present supplied by Provista, which can enable physicians to achieve a extra complete view of a affected person’s situation that may allow higher focused, quicker remedy selections.
Sepsis poses an amazing human and monetary burden to the healthcare system because the #1 explanation for demise in hospitals, stated Gerald Commissiong, President & CEO of Todos Medical. As Provista expands its pipeline of proprietary checks that it intends to launch through the Laboratory Developed Check (LDT) pathway within the US, our rising gross sales drive may be very excited to work with hospitals and long-term care services to enhance the screening and prognosis of sepsis , permitting for earlier therapeutic interventions which have higher profit within the earliest levels of sepsis, lowering the chance of a affected person present process septic shock. On this period of COVID-19 and widespread antibiotic resistance, we imagine that sepsis has grow to be an much more urgent medical problem and that it might additionally play a job within the worst outcomes of Lengthy COVID. After an intensive analysis of applied sciences for diagnosing sepsis, we got here to the conclusion that AcuSept has the potential to contribute in an impactful solution to assembly this vital unmet want for improved sepsis prognosis.
We’re more than happy to companion with Provista to convey our AcuSept take a look at to the US, stated Dr. Ong Hwa Siew, CEO of Acumen Diagnostics. We spent a number of days with the Provista crew evaluating their laboratory capabilities and assembly with physicians in Atlanta concerning the implementation of AcuSept to help within the screening and prognosis of sepsis in long-term care services, acute care facilities and hospitals. It was clear that the Provista crew is nicely built-in into the Atlanta healthcare group and has the relationships essential to efficiently launch AcuSept within the US.
For extra info, please go to todosmedical.com. For extra info on the Firm’s 3CL Protease Inhibitor Dietary Complement that gives immune assist with 3CL Protease Inhibition. please go to www.mytollovid.com.
About Todos Medical Ltd.
Todos Medical Ltd. (OTCQB: TOMDF) is based in Rehovot, Israel with places of work in New York Metropolis, and develops life-saving diagnostic options for the early detection of quite a lot of cancers. The corporate’s state-of-the-art and patented Todos Biochemical Infrared Analyzer (TBIA) is a proprietary most cancers screening know-how utilizing peripheral blood evaluation that examines the affect of most cancers on the immune system and appears for biochemical modifications in mononuclear blood cells and plasma. Todos two in-house developed most cancers screening checks, TMB-1 and TMB-2, have acquired a CE mark in Europe. Todos just lately acquired the American medical diagnostics firm Provista Diagnostics, Inc. to acquire rights to its Alpharetta, Georgia-based CLIA/CAP-certified laboratory that at present performs PCR COVID testing, Lengthy COVID Panel assays and Provista’s proprietary Videssa breast most cancers blood in industrial part. pattern. Extra details about Provista is offered at www.provistadx.com.
Todos can also be creating blood checks for the early detection of neurodegenerative problems, comparable to Alzheimer’s illness. The lymphocyte proliferation take a look at (LymPro Check) is a diagnostic blood take a look at that determines the flexibility of peripheral blood lymphocytes (PBLs) and monocytes to face up to an exogenous mitogenic stimulation that causes them to enter the cell cycle. It’s believed that sure illnesses, significantly Alzheimer’s illness, are the results of compromised mobile equipment that results in aberrant cell cycle re-entry of neurons, which then results in apoptosis. LymPro is exclusive in its use of peripheral blood lymphocytes as a surrogate for neuronal cell perform, suggesting a typical relationship between PBLs and neurons within the mind.
Todos shaped the Israel-based majority-owned three way partnership 3CL Pharma Ltd with NLC Pharma in March 2022 to consolidate all mental property round 3CL protease-based diagnostic testing and growth of 3CL protease botanical and pharmaceutical inhibitors focusing on a basic reproductive mechanism of the coronavirus. . 3CL Pharma, by the Todos model, has commercialized the 3CL protease inhibitor immune assist dietary complement Tollovid within the US, is creating the twin mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir, whereas concurrently creating the 3CL protease diagnostic TolloTest.
To purchase Tollovid please go to Amazon or www.MyTollovid.com.
For extra info, please go to https://todosmedical.com/.
Ahead-looking statements
Sure statements contained on this press launch might represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated medical growth applications and medical trials. These forward-looking statements are based mostly solely on the present expectations of administration and are topic to important dangers and uncertainties that would trigger precise outcomes to vary materially from these described in such forward-looking statements, together with the dangers and uncertainties associated to progress, timing, prices and outcomes of medical trials and product growth applications; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology corporations; and our means to acquire further financing essential to conduct our analysis, growth and commercialization actions. As well as, components comparable to the next might trigger precise outcomes to vary materially from these described within the forward-looking statements: modifications in know-how and market necessities; delays or obstacles within the launch of our medical trials; modifications in laws; lack of ability to well timed develop and introduce new applied sciences, merchandise and purposes; failure to validate our know-how as we make additional progress and failure to simply accept our strategies by the scientific group; lack of ability to retain or appeal to key staff whose data is vital to the event of our merchandise; unexpected scientific difficulties that will develop with our course of; greater prices of the ultimate product than anticipated; lack of market share and strain on pricing ensuing from competitors; and laboratory outcomes that don’t translate equally nicely to ends in real-world settings, all of which might trigger precise outcomes or efficiency to vary materially from these anticipated in such forward-looking statements. Besides as in any other case required by legislation, Todos Medical undertakes no obligation to publicly announce any modifications to those forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the prevalence of unforeseeable occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please consult with its experiences filed sometimes with the US Securities and Trade Fee.
Todo’s company and investor contact:
Gerald Commissiong
President & CEO
gerald@todosmedical.com
